Quality of life

argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thrombocytopenia

Retrieved on: 
Tuesday, March 26, 2024
Diagnosis, Blood pressure, Efgartigimod alfa, System, Urination, Urinary tract infection, MHLW, Chest pain, Rituximab, Allergy, Disease, Infection, Risk, Headache, Patient, Sore throat, IWG, History, ITP, Chills, Quality of life, Cough, Euronext, Rash, Respiratory tract infection, Splenectomy, Medicine, Skin, Fever, Antibody, Wheeze, Back pain, Shivering, Safety, Pain, Fatigue, Phlegm, Swelling, Food, Autoimmune disease, Nursing

“argenx is on a mission to deliver transformative medicines for people living with severe autoimmune disease,” said Tim Van Hauwermeiren, Chief Executive Officer of argenx.

Key Points: 
  • “argenx is on a mission to deliver transformative medicines for people living with severe autoimmune disease,” said Tim Van Hauwermeiren, Chief Executive Officer of argenx.
  • By reducing circulating autoantibodies, VYVGART is uniquely designed to serve as a precision intervention that targets the underlying disease biology of ITP.
  • ADVANCE successfully met its primary endpoint, demonstrating that a higher proportion of chronic ITP patients receiving VYVGART achieved a sustained platelet count response compared to placebo.
  • Do not use VYVGART if you have a serious allergy to efgartigimod alfa or any of the other ingredients in VYVGART.

U.S. Congressman Josh Gottheimer Champions Rare Disease Research With Sponsorship of Legislative Bill - H.Res.1039 - Advocating for Increased Funding for Charcot-Marie-Tooth Disease (CMT)

Retrieved on: 
Tuesday, April 9, 2024
Dental, Public Policy, Government, Healthcare Reform, Philanthropy, Biotechnology, Other Health, Health, General Health, Foundation, Stroke, Brain, NJ-5, Gene, Charcot–Marie–Tooth disease, Disease, Sympathetic nervous system, DSM-IV codes, Research, Hope, Quality of life, Hunting, Tax, Child, Spinal cord, Rare Disease Caucus, Legislation, Disability, ID, Bangladesh Technical Education Board, Hearing, CMT, Pharmaceutical industry

The resolution underscores the urgency of addressing the challenges of individuals diagnosed with Charcot-Marie-Tooth disease (CMT) and the need for robust research funding.

Key Points: 
  • The resolution underscores the urgency of addressing the challenges of individuals diagnosed with Charcot-Marie-Tooth disease (CMT) and the need for robust research funding.
  • “By collaborating with experts and advocates, we can give everyone struggling with Charcot-Marie-Tooth Disease hope.
  • Zaken's dedication reflects the grassroots efforts of young individuals committed to making a difference in the fight against rare diseases.
  • Regrettably, despite its profound impact, federal funding for CMT research witnessed a decrease in 2022 compared to 2021.

Atlantic Health System Adopts FeelBetter’s Precision Population Health Platform to Optimize and Personalize Medication Management

Retrieved on: 
Tuesday, April 9, 2024
Health, Technology, Practice Management, Health Technology, General Health, Artificial Intelligence, Pharmaceutical, Diagnosis, ACO, Atlantic Ocean, Entrepreneurship, Acos, Atlantic Health System, Partnership, Physician, Patient, AI, Death, Quality of life, Pharmacology, Polypharmacy, Medicare, Hospital, Nursing

FeelBetter , the leading provider of polypharmacy patient management technology and pioneer of Pharmaco-Clinical Intelligence, today announced a commercial partnership with Atlantic Health System (“Atlantic Health”).

Key Points: 
  • FeelBetter , the leading provider of polypharmacy patient management technology and pioneer of Pharmaco-Clinical Intelligence, today announced a commercial partnership with Atlantic Health System (“Atlantic Health”).
  • The not-for-profit health system, which provides care for more than half the state of New Jersey and parts of New York and Pennsylvania, is leveraging FeelBetter’s AI-based precision population health platform to optimize and personalize medication management for polypharmacy patients across Atlantic Health System aligned Accountable Care Organizations (ACO).
  • “At Atlantic Health System, adopting new AI-based technologies with the potential to enhance healthcare is part of our unwavering commitment to providing high quality, safe, affordable patient care,” said Dr. Thomas Kloos, President, Vice President, Atlantic Health System and President, Atlantic Accountable Care Organization.
  • In the US alone, every year, suboptimal medication management results in 275,000 deaths and more than $528B in avoidable costs .

AscellaHealth Recognized by The Financial Times for Three Consecutive Years as One of “Americas' Fastest Growing Companies”

Retrieved on: 
Tuesday, April 9, 2024
Other Manufacturing, Research, Manufacturing, Biotechnology, Managed Care, Health, Pharmaceutical, Science, Oncology, Financial Times, Quality of life, Patient, Multimedia, Growth, Government, Pharmacy

The data was collected via desk research in official sources like publicly available earning presentations, investor relations, websites and annual reports.

Key Points: 
  • The data was collected via desk research in official sources like publicly available earning presentations, investor relations, websites and annual reports.
  • “Every day our team gets critical healthcare products from manufacturers to patients while ensuring an efficient flow of funds between payers and pharma,” says Belazi.
  • “We partner with life sciences manufacturers around the world, enabling them to successfully commercialize therapies for complex, chronic conditions.
  • Concurrently, we are raising the bar and resetting standards for managing pharmacy costs through our comprehensive suite of services for payers, including government and private insurers.”

NanoVibronix Issues Letter to Stockholders

Retrieved on: 
Tuesday, April 9, 2024
Medical Devices, Health, Health Technology, Research, Science, Biotechnology, National Health Service, Growth, Partnership, COVID-19, Patient, SAW, Gold, NHS, University, University of Michigan, Quality of life, Insurance, GSA, Urinary tract infection, Pain, Medicare, FDA, CMS, Engineering, Food, Pharmaceutical industry

We are focused on several areas that we believe will have a substantial impact on our growth and product adoption.

Key Points: 
  • We are focused on several areas that we believe will have a substantial impact on our growth and product adoption.
  • A driving factor in our increased revenues was increased sales to customers using the Veterans’ Health System and worker’s compensation plans.
  • On our balance sheet for the period ended December 31, 2023, we had $3.3 million of cash and inventory of $2.7 million.
  • CMS invited NanoVibronix to a public meeting to present its findings and to answer CMS’s questions, which was held June 1, 2023.

Lundbeck to Present Data on Migraine Impact Reduction and Sustained Response with VYEPTI® (eptinezumab-jjmr) at 76th Annual Meeting of the American Academy of Neurology

Retrieved on: 
Tuesday, April 9, 2024
Health, Other Science, General Health, Clinical Trials, Research, Science, Pharmaceutical, Hypersensitivity, Anaphylaxis, Angioedema, Brain, Eptinezumab, Virtual Private LAN Service, Headache, Patient, American Academy, Interview, MD, Neurology, Migraine, Lundbeck, Quality of life, AAN, Abstract, Pharmaceutical industry

These data will be presented during an oral session at the 76th Annual Meeting of the American Academy of Neurology (AAN) taking place in Denver, Colo., and virtually from April 13-18, 2024.

Key Points: 
  • These data will be presented during an oral session at the 76th Annual Meeting of the American Academy of Neurology (AAN) taking place in Denver, Colo., and virtually from April 13-18, 2024.
  • “Our real-world data helps us better understand how individuals are uniquely impacted by migraine beyond monthly headache days.
  • We’re excited to continually partner with the migraine community to raise the bar on preventive treatment expectations.”
    VYEPTI is indicated for the preventive treatment of migraine in adults.
  • The safety and efficacy of VYEPTI has not been evaluated for use in any psychiatric conditions.

Global Diabetic Footwear Market Research Report 2024: Technological Innovations Propel Demand - Long-term Forecast to 2028 and 2032 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, April 9, 2024
Retail, Footwear, Diabetes, Health, Growth, Risk, Sale, Quality of life, Shoe, Ageing, Pharmaceutical industry

The "Diabetic Footwear Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Diabetic Footwear Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering.
  • This upward trajectory reflects the escalating demand attributed to the growing global diabetic population and technological innovation within the industry.
  • Several key factors are driving the expansion of the diabetic footwear market.
  • In addition, the rise in e-commerce has significantly enhanced the accessibility and availability of diabetic footwear across various demographics worldwide.

Ferring Presents Pivotal Phase 3 Efficacy and Safety Data for Investigational Treatment, SI-6603 (condoliase), in Lumbar Disc Herniation at ASIPP 2024

Retrieved on: 
Monday, April 8, 2024
Biotechnology, Men, Health, Consumer, Other Health, Pharmaceutical, Surgery, Other Science, Research, Medical Devices, Science, Women, Seniors, Clinical Trials, Week, Sciatica, LDH, Incidence, Ferring Pharmaceuticals, Patient, Spinal disc herniation, Șaeș, University, ESI, Quality of life, Manager, University of Illinois Urbana-Champaign, Society, Back pain, LSM, Pain, SAE

"Based on these findings, SI-6603 could provide another option where a single injection to the lumbar disc could offer patients significant relief from the unrelenting pain often associated with lumbar disc herniation."

Key Points: 
  • "Based on these findings, SI-6603 could provide another option where a single injection to the lumbar disc could offer patients significant relief from the unrelenting pain often associated with lumbar disc herniation."
  • An analysis assessing current treatment patterns and gaps in clinical management of patients with newly diagnosed LDH was also presented.
  • The analysis reviewed medical claims data of more than a million U.S. patients over a four-year period.
  • Among patients who received more than one ESI, one in five (22.4%) underwent surgery with 14.2% of those patients receiving repeated surgeries.

Health New England Partners with Wellth to Give its BeHealthy Partnership ACO Members New Tools to Build Healthy Habits and Improve Outcomes

Retrieved on: 
Tuesday, April 9, 2024
Health, Partnership, Loss aversion, Transport, Baystate Health, Food, Quality of life, Emergency department, Medicaid, Habit, Machine learning, Medicare, Medicine

SPRINGFIELD, Mass., April 9, 2024 /PRNewswire/ -- Health New England, the regional not-for-profit health plan serving western Massachusetts with commercial, Medicare and Medicaid plans, today announced a partnership with Wellth, the leading science-backed behavioral change solution that empowers members to prioritize their health and manage chronic conditions. The collaboration will help BeHealthy Partnership (Health New England's Medicaid ACO) plan members build lasting healthy habits, strengthen treatment plan adherence, and reduce unnecessary health care costs.

Key Points: 
  • The collaboration will help BeHealthy Partnership (Health New England's Medicaid ACO) plan members build lasting healthy habits, strengthen treatment plan adherence, and reduce unnecessary health care costs.
  • BeHealthy Partnership plan members will gain access to Wellth's customized and easy-to-use digital health solution, which rewards members for taking daily steps toward improving their well-being.
  • Together, we will help our members build healthy long-term habits that will improve treatment outcomes, reduce costs, and strengthen our connection with our valued members even further."
  • Wellth is proud to partner with Health New England to help its BeHealthy Partnership members follow their daily care plans to improve their quality of life and develop lifelong sustainable behaviors.

Commitment to Employee Health and Well-being Recognized

Retrieved on: 
Tuesday, April 9, 2024
Well, Disability, Culture, Freedom, BGH, Partnership, Mental health, News, Quality of life, Carbon, Fiat, UAW, STLA, Ram, Alfa Romeo, Nursing

The company is receiving the prestigious Best Employers: Excellence in Health and Well-being Award for its outstanding commitment to advancing employee well-being through comprehensive and innovative benefits and initiatives, and the Excellence in Health Equity for working to ensure that all employees have the opportunity to reach their full health potential, incorporating diversity, equity, inclusion and belonging into health and well-being strategies.

Key Points: 
  • The company is receiving the prestigious Best Employers: Excellence in Health and Well-being Award for its outstanding commitment to advancing employee well-being through comprehensive and innovative benefits and initiatives, and the Excellence in Health Equity for working to ensure that all employees have the opportunity to reach their full health potential, incorporating diversity, equity, inclusion and belonging into health and well-being strategies.
  • "Promoting and supporting the health and well-being of our employees and their families is central to our company's culture and success."
  • Stellantis is one of 54 companies to earn the Best Employers: Excellence in Health and Well-being Award and one of 13 companies being additionally recognized for Excellence in Health Equity.
  • "In addition, their novel and impactful approaches focused on critical workforce issues, such as mental health and health equity.